Rezolute (RZLT) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
21 Oct, 2026Executive summary
Virtual annual meeting set for Dec. 2, 2026; record date Oct. 5, 2026, with 96,728,913 common shares outstanding and entitled to vote.
Stockholders are asked to elect seven directors, ratify Grant Thornton for FY ending June 30, 2027, cast an advisory say-on-pay vote, approve a 60 million-share authorization increase, and authorize adjournment if needed to solicit votes.
The Board recommends FOR all five proposals.
Voting matters and shareholder proposals
Seven nominees seek election; directors are elected by plurality, with the nominees receiving the most affirmative votes elected.
Grant Thornton ratification and say-on-pay each require a majority of votes cast; say-on-pay is non-binding, and compensation will be reexamined if stockholders do not approve it.
Share increase approval requires a majority of outstanding common shares; abstentions and broker non-votes have the same effect as votes against.
Adjournment requires a majority of votes cast; abstentions and broker non-votes have no effect.
Proxies may be submitted by mail, telephone, internet, or at the virtual meeting; electronic and telephone votes are due by 11:59 p.m. ET Dec. 1, 2026.
Board of directors and corporate governance
Seven nominees: Nevan Charles Elam, Erik Harris, Gil Labrucherie, Nerissa Kreher, Philippe Fauchet, Wladimir Hogenhuis, and Young-Jin Kim.
Elam is CEO and Acting Chair; the Board supports combining the roles currently and will periodically reconsider the structure.
Five directors were identified as independent as of June 30, 2026; Elam and Kim were identified as non-independent.
The Board held seven meetings in FY2026; directors attended at least 75% of Board and committee meetings on which they served.
The Nominating and Governance Committee considers diversity of race, ethnicity, gender, age, cultural background, and professional experience, without a formal written diversity policy.
Latest events from Rezolute
- Ersodetug advances in two late-stage HI programs, with upLIFT topline results expected in 2H 2026.RZLT
Corporate presentation - Board seeks approval to add 60M authorized shares amid financing needs and dilution trade-offs.RZLT
Proxy filing - Late-stage antibody therapy targets refractory hypoglycemia in HI, with $1B+ global potential.RZLT
Corporate presentation - Positive interim tumor HI results and ongoing FDA review for congenital HI amid rising net loss.RZLT
Q4 2026 - Late-stage antibody therapy targets refractory hypoglycemia in HI, with $1B+ market potential.RZLT
Corporate presentation - Pivotal data and regulatory milestones support dual BLA filings and strong market prospects in 2025.RZLT
Jefferies Global Healthcare Conference 2026 - Phase 3 data showed strong efficacy for ersodetug in HI; net loss narrowed as R&D costs fell.RZLT
Q3 2026 - Ersodetug advances in Phase 3 for HI, targeting a $1B+ rare disease market with FDA engagement.RZLT
Corporate presentation - Late-stage antibody therapy targets severe hypoglycemia in rare hyperinsulinism, with $1B+ potential.RZLT
Corporate presentation